Drug Trial Radar · NCT03678753
Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures
Last checked: Nov 19, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
169
Actual
Start
Oct 3, 2018
Primary completion
May 26, 2025
Study completion May 26, 2025
Sponsor
- Lead sponsor
- SK Life Science, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 20, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is intended to study the safety and effectiveness of an new anti-epileptic drug (AED) on Primary Generalized Tonic-Clonic (PGTC) Seizures. Eligible Subjects, adults and adolescents, will continue to take their usual AEDs and receive either cenobamate or placebo. Subjects will have a 50% chance or receiving cenobamate or placebo (sugar pill). Subjects will initially receive 12.5 mg of cenobamate or placebo (study drug) and increase the dose every two weeks until they reach a target dose of 200 mg. Subjects will take study drug at approximately the same time in the morning (once a day) with or without food. If tolerability issues arise, dosing can be changed to evening. Also, once a subject reaches 200 mg, the dose can be decreased one time to 150 mg, if necessary. The treatment period is 22 weeks and there is a 3 week follow up period, which includes a one week decrease in study drug to 100 mg prior to stopping. Adolescents will follow the same every two week regimen and receive cenobamate as an oral suspension based on weight. Subjects who complete may be eligible for an extension study and will not have to complete the follow up period. Subjects will track their seizure types and frequency in a diary throughout the study.
Conditions
- Primary Generalized Epilepsy
Interventions
CenobamateDrug
12.5 mg tablet, 25 mg tablet, 50 mg tablet, 100 mg tablets, 150 mg tablets, 200 mg tablets. Adolescents will follow the same every two week regimen and receive cenobamate as an oral suspension based on weight.
PlaceboDrug
Matching Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- USA and Rest of World (RoW): Percent Change in PGTC Seizure Frequency Per 28 Days During the Double-blind Treatment Period Relative to Baseline.Time frame: Baseline and 22-week Double-blind Treatment Period.
- Europe, South Africa, Australia, and New Zealand: 50% Responder Rate for PGTC Seizures During the Maintenance Phase Relative to Baseline.Time frame: Baseline and 12-week Maintenance Phase.
Locations
116 sites in 12 countries. Site status is shown where the registry gives one.
Phoenix Children's Hospital
Phoenix, Arizona
Center for Neurosciences
Tuscon, Arizona
Neuro Pain Medical Center
Fresno, California
Colorado Springs Neurological Associates
Colorado Springs, Colorado
Children's Hospital of Colorado
Grand Junction, Colorado
Brainstorm Research
Miami, Florida
Florida Hospital Medical Group
Orlando, Florida
University of South Florida
Tampa, Florida
Clinical Integrative Research Center of Atlanta, CIRCA
Atlanta, Georgia
Children's Healthcare of Atlanta
Atlanta, Georgia
Hawaii Pacific Neuroscience
Honolulu, Hawaii
Consultants in Epilepsy and Neurology
Boise, Idaho
Rush University
Chicago, Illinois
Indiana University
Indianapolis, Indiana
PMG Research of McFarland Clinic
Ames, Iowa
University of Kentucky
Lexington, Kentucky
Maine Medical Center
Scarborough, Maine
Mid-Atlantic Epilepsy and Sleep Center
Bethesda, Maryland
Michigan State University
East Lansing, Michigan
Minneapolis Clinic of Neurology Golden Valley
Golden Valley, Minnesota
Mayo Clinic - Rochester
Rochester, Minnesota
University of Missouri Health Care
Columbia, Missouri
JFK Medical Center- The Neuroscience Institute
Edison, New Jersey
Northeast Regional Epilepsy Group
Hackensack, New Jersey
Saint Peter's University Hospital
New Brunswick, New Jersey
New York Presbyterian Hospital
Brooklyn, New York
UBMD Neurology
Buffalo, New York
Five Towns Neuroscience Research
Woodmere, New York
Duke University Children's Health Center
Durham, North Carolina
Ohio Health Research and Innovation Institute
Columbus, Ohio
University of Toledo
Toledo, Ohio
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania
Thomas Jefferson University
Philadelphia, Pennsylvania
Temple University Lewis Katz School of Medicine
Philadelphia, Pennsylvania
LeBonheur Children's Medical Center
Memphis, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee
Child Neurology Consultants of Austin
Austin, Texas
ANRC Research
El Paso, Texas
Baylor College of Medicine
Houston, Texas
University of Utah / Primary Children's Hospital
Salt Lake City, Utah
Showing 40 of 116 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.